Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: Implications for endometrial cancer treatment

Journal of Gynecologic Oncology

Volumn 21, Issue 1, 2010, Pages 45-49

  Ballard, Karen S ^a   Hornesley, Howard D ^a   Hodson, Charles ^a   Presant, Cary A ^b   Rutledge, James ^c   Hallquist, Allan ^b   Perree, Mathieu ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b DiaTech Oncology   (United States)

^c Statistician Data Vision   (United States)

Author keywords

Chemosensitivity assay; Chemotherapy; Endometrial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; PACLITAXEL; VINCRISTINE;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL SUSPENSION; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE;

EID: 77953388269     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.1.45     Document Type: Article

References (22)

1. Kravtsov VD. A novel microculture kinetic assay (MiCK assay) for malignant cell growth and chemosensitivity. Eur J Cancer 1994; 30A: 1564-1570
2. 2. Kravtsov VD, Fabian I. Automated monitoring of apoptosis in suspension cell cultures. Lab Invest 1996; 74: 557-570 (Pubitemid 26072096)
3. Kravtsov VD, Greer JR Whitlock JA Koury MJ. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Blood 1998; 92: 968-980
4. Kravtsov VD, Daniel TO, Koury MJ. Comparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosis. Am J Pathol 1999; 155: 1327-1339
5. Kravtsov VD, Priego V, Reilly GJ, Sethi H, Cooke J, Smith W, et al. Chemotherapy of myeloid leukemia directed by a microculture kinetic (MiCK) assay for apoptosis. The 42nd American Society of Hematology Meeting 2000, Abstract 3129.
6. Kravtsov VD, Greer JR Shyr Y, Haselton DJ, Whitlock JA, Goodman SA et al. Prediction of survival and responses to chemotherapy in acute myelogeneous leukemia (AML) by the microculture kinetic (MiCK) assay of apoptosis. The 40th American Society of Hematology Meeting 1998, Abstract 2790.
7. Kravtsov VD, Greer JR Shyr Y, Whitlock JA, McCurley TL, Goodman SA et al. Prediction of survival in acute non-lymphocytic leukemia. The 43rd American Society of Hematology Meeting 2001, Abstract 4572.
8. 8. Zhang J, Kravtsov V, Amarnath V, Picklo MJ, Graham DG, Montine TJ. Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease. J Neurochem 2000; 74: 970-978 (Pubitemid 30104292)
9. Schultz R, Rothenberg M, Koury M, Hankins WD, Kravtsov V. Sequence dependence using combinations of Alimta™ (pemetrexed disodium, LY231514, MTA), gemcitabine, and oxaliplatin in human colorectal carcinoma cell lines. The 11th National Cancer Institute-European Organization for Research and Treatment of Cancer-American Association for Cancer Research Symposium, Abstract 503.
10. SAS. JMR Version 7. Cary: SAS Institute Inc.; 1989-2007.
11. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945; 1: 80-83
12. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998; 52: 119-126
13. 13. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 278-281 (Pubitemid 26274811)
14. Broun GO, Blessing JA Eddy GL Adelson MD. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Am J Clin Oncol 1993; 16: 18-21.
15. 15. Fleming GF, Brunetto VL Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159-2166 (Pubitemid 41095150)
16. 16. Lincoln S, Blessing JA Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 277-281 (Pubitemid 36335809)
17. 17. Sutton GP, Blessing JA DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996; 63: 25-27 (Pubitemid 26337960)
18. 18. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3902-3908 (Pubitemid 41079871)
19. 19. Thigpen JT, Blessing JA Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 1989; 33: 68-70. (Pubitemid 19106626)
20. Presant CA, Bosserman L, Howard F, Emilio B. Patterns of metastatic (met) disease sites in breast cancer (BrCa): implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (Tp) in met disease. J Clin Oncol 2009; 27 Suppl: abstr e12004.
21. Latimer RG, Presant CA, Hallquist AE, Perree M, Agapitos D. The value of personalized treatment (Rx) planning (PTP): cost savings (sav) by the microculture kinetic (MiCK) chemosensitivity (CS) assay, evidence from a large american self-insured company (ASIC). J Clin Oncol 2009; 27 Suppl: abstr e17541.
22. Whitworth PW, Presant CA, Rudedge J, Hallquist A, Perree M, Agapitos D. Chemosensitivity (CS) of patient (pt) breast cancer (BrCa) cells in vitro: correlation with prior chemotherapy (CT) and implications for personalized treatment planning. J Clin Oncol 2009; 27 Suppl: abstr e11563.